Targeted Therapy Shows Durable Survival Benefit in Rare Lung Cancer Subtype
For patients diagnosed with a specific genetic form of advanced lung cancer, new long-term data suggests a targeted therapy may extend median survival significantly beyond historical expectations. In a recent evaluation of the drug pralsetinib, researchers found that patients with RET fusion-positive non-small cell lung cancer (NSCLC) lived a median of 44 months even as on treatment.
This represents a substantial shift from the historical outlook for this condition. Before selective RET inhibitors were available, the expected overall survival for advanced RET fusion-positive NSCLC typically ranged between 4 and 11 months. The findings come from the final efficacy and safety data of the Phase I/II ARROW study, conducted by researchers at Mass General Brigham Cancer Institute and published in the Journal of Clinical Oncology.
The study followed 281 patients with advanced or metastatic RET fusion-positive NSCLC over a 42-month period. Pralsetinib, which is already FDA-approved, targets the RET gene changes that drive tumor growth in this subset of patients. The data indicates that the drug produces durable responses, particularly in patients who had not received prior treatment.
Overall response rates varied based on treatment history. Among patients who had not received prior therapy, 78% responded to pralsetinib. For those who had previously undergone chemotherapy, the response rate was 63%. The drug similarly showed activity in patients with brain metastases, a common and difficult-to-treat complication, with a 73% response rate observed in this group.
Context: The Role of Biomarker Testing
RET fusions are rare genetic alterations, found in approximately 1% to 2% of non-small cell lung cancer cases. Because these mutations are not detectable through standard imaging, comprehensive biomarker testing is required to identify them. Medical oncologists recommend molecular profiling for all patients with metastatic NSCLC to determine if targeted therapies like pralsetinib are appropriate options before starting standard chemotherapy.
While the survival benefits are notable, the safety profile requires careful management. Common treatment-related adverse effects included anemia, hypertension, and reduced neutrophil count. In the study, 51% of patients required a dose reduction to manage side effects, and 10% discontinued treatment entirely. Three patients died from causes related to the treatment.
Researchers noted that pralsetinib did not cause hypersensitivity in patients who had been exposed to prior immunotherapies. This distinguishes it from some other RET inhibitors that have shown similar complications. However, the study authors emphasize that further research is needed to understand why some tumors eventually develop resistance to the medication.
Questions for Patients and Clinicians
Who is eligible for this treatment?
This therapy is indicated for patients with metastatic NSCLC whose tumors have been confirmed to harbor RET gene fusions through molecular testing.
How does this compare to previous standards?
The median survival of 44 months observed in this study exceeds the historical median survival of 4 to 11 months associated with this condition prior to the availability of selective RET inhibitors.
What are the primary safety concerns?
Patients should be monitored for hypertension, anemia, and neutrophil counts. Dose adjustments are common to maintain tolerability.
As targeted therapies continue to evolve, the emphasis remains on identifying the right patients early enough to benefit from these interventions. With survival timelines extending into years rather than months, the window for effective management widens, provided the genetic drivers are identified at the outset.
For families navigating a new diagnosis, how might early access to comprehensive genetic testing change the conversation about long-term treatment planning?
